Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results

SEATTLE, Oct. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Wednesday, November 3, 2010 at 4:30 p.m. ET to review third quarter financial results.  

Access to the discussion may be obtained as follows:

Time:

4:30 PM ET / 1:30 PM PT

Date:

November 3, 2010

Dial-in:

1-866-730-5769 (domestic) or +1-857-350-1593 (international); conference pass code: 35737817

Webcast:

www.dendreon.com (homepage and investor relations section)



A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1- 888-286-8010 or +1-617-801-6888 for international callers; the conference ID number is 97336729. The replay will be available from 7:30 pm ET on Wednesday, November 3rd until 11:59 pm ET on Wednesday, November 10th.  In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010.  Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

SOURCE Dendreon Corporation

Suggested Articles

Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development in asthma.

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.